22.1 percent of EBV D+\/R\u2212 kidney recipients had posttransplant lymphoproliferative disorder at median of 202 days after transplant<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, Feb. 5, 2025 (HealthDay News) — Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+\/R\u2212) kidneys have an increased risk for posttransplant lymphoproliferative disorder (PTLD), according to a study published online Jan. 28 in the Annals of Internal Medicine<\/em>.<\/p>\n Vishnu S. Potluri, M.D., M.P.H., from the Hospital of the University of Pennsylvania, and colleagues conducted a retrospective cohort study to examine the associations between pretransplant EBV D+\/R\u2212 and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival in adult recipients of kidney transplant.<\/p>\n The final cohort included 104 EBV D+\/R\u2212 recipients matched to 312 EBV R+ recipients. The researchers found that 50 (48.1 percent) of the EBV D+\/R\u2212 recipients developed EBV DNAemia, with a median time of 198 days after transplant. At a median of 202 days after transplant, 23 (22.1 percent) EBV D+\/R\u2212 recipients had PTLD. Higher all-cause graft failure was seen in EBV D+\/R\u2212 recipients (hazard ratio, 2.21; 95 percent confidence interval, 1.06 to 4.63), and mortality was higher but the increase was not statistically significant (hazard ratio, 2.19; 95 percent confidence interval, 0.94 to 5.13).<\/p>\n “Our findings highlight the need for strategies to attenuate the effect of donor-derived EBV infection among EBV-seronegative recipients and for counseling prospective EBV D+\/R\u2212 recipients about the elevated risk for early PTLD,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n